ALEC Stock Analysis: Buy, Sell, or Hold?
ALEC - Alector, Inc. Common Stock
$2.03
0.02 (1.25%)
▲
5d:
-1.7%
30d:
-16.67%
90d:
+39.66%
BUY
HIGH Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: May 14, 2026
Smart Money Accumulation
ALEC is down 8.8% this week, but smart money is accumulating calls. Top strike: $2.5 2026-04-17 with 1,410 OI. Call ratio: 99% View Scanner →
Strength: 9.3/10
Get Alerted When ALEC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ALEC shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: ALEC shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
In-depth Analysis How we analyze
Valuation Analysis: ALEC is currently trading at $2.02, which is considered slightly low relative to its 30-day fair value range of $2.02 to $2.31.
Technical Outlook: Technically, ALEC is in a strong uptrend. Immediate support is located at $1.95, while resistance sits at $2.28.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $2.88 (+44.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ALEC is in a strong uptrend. Immediate support is located at $1.95, while resistance sits at $2.28.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $2.88 (+44.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$2.02 -
$2.31
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
86.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 44.0% below Wall St target ($2.88)
Fair Price Analysis
30-Day Fair Range
$2.02 -
$2.31
Current vs Fair Value
SLIGHTLY LOW
Expected Move (7 Days)
±$0.36
(17.9%)
Support & Resistance Levels
Support Level
$1.95
Resistance Level
$2.28
Current Trend
Strong Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.20
Wall Street Target
$2.88
(+44.0%)
Revenue Growth (YoY)
-88.5%
Earnings Growth (YoY)
-86.3%
Share & Embed Analysis
Last updated: March 30, 2026 12:00 PM ET
Data refreshes hourly during market hours. Next update: 1:00 PM
Data refreshes hourly during market hours. Next update: 1:00 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ALEC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
7
Sells
Net
INSIDERS SELLING
Recent Transactions
Grace Wong-Sarad
SELL
1000 shares
2026-03-10
Grace Wong-Sarad
SELL
4079 shares
2026-02-26
Grace Wong-Sarad
SELL
4753 shares
2025-12-05
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$222 | 62 BUY |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$92 | 62 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$54 | 54 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 56 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$84 | 61 BUY |
